Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-02-09 00:00:00 ET · period of report 2024-02-07 · accession 0001209191-24-003053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.22 | -48.3K | 774.7K | -6% | -$445.1K |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 823.0K | +4% | +$77.5K |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 791.7K | -1% | $0 |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 801.7K | +1% | $0 |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -10.0K | 6.47M | -0.2% | $0 |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $0.00 | -31.2K | 343.8K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-02-07 | S | D | 48,272 | $9.22 | 774,703 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $9.07 to $9.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2024-02-07 | M | A | 31,250 | $2.48 | 822,975 | D | — | — | |
| 3 | Common | Class A Common Stock | 2024-02-07 | G | D | 10,000 | $0.00 | 791,725 | D | — | — | |
| 4 | Common | Class A Common Stock | 2024-02-07 | C | A | 10,000 | $0.00 | 801,725 | D | — | — | |
| 5 | Derivative | Class B Common Stock | 2024-02-07 | C | D | 10,000 | $0.00 | 6,471,496 | D | $0.00 · — to — | 10,000 Class A Common Stock | (F8) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-02-07 | M | D | 31,250 | $0.00 | 343,750 | D | $2.48 · — to 2030-12-30 | 31,250 Class A Common Stock | (F6) The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |